Results 151 to 160 of about 12,417 (199)

Risk factors and a model for prognosis prediction after intravenous thrombolysis with alteplase in acute ischemic stroke based on propensity score matching

Pan Huang, Xingyang Yi
openalex   +1 more source

Reversal of ischemic cortical blindness with tenecteplase. [PDF]

Am J Ophthalmol Case Rep
Tang R, Naser M, Alryalat SA, Al Deyabat O, Lee AG.   +4 more
europepmc   +1 more source

The Importance of Cost-Effectiveness in New Drug Approval: Stroke Burden and Tenecteplase Efficacy. [PDF]

J Clin Neurol
Kwon HS, Kim BJ.
europepmc   +1 more source

Comparison of nicardipine versus labetalol for time to alteplase administration in acute ischemic stroke. [PDF]

Front Neurol
Huang A, Parker D, Wein R.
europepmc   +1 more source

Fingolimod as a Neuroprotective Agent in Ischemic Stroke: A Review of Preclinical and Clinical Evidence. [PDF]

J Clin Med
Ciubotaru A, Covali R, Grosu C, Alexa D, Pilă EF, Cucu AI, Bobu AM, Sargu GD, Riscanu L, Tirnovanu MC, Adam C, Popa R, Filip C, Ignat EB.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Alteplase

Expert Opinion on Investigational Drugs, 1997
Alteplase (recombinant human tissue type plasminogen activator, rt-PA) was identified as a naturally occurring plasminogen activator in 1975, cloned from a human melanoma cell line in 1981, introduced into clinical trials in 1982, and received a product licence for the treatment of acute myocardial infarction in 1986.
openaire   +3 more sources

Alteplase

Reactions Weekly, 2018
  +7 more sources

Alteplase

Reactions Weekly, 2023
  +5 more sources

Alteplase

Reactions Weekly, 2022
Michelle C. Simpson, Eric G. Schaefer
  +4 more sources